Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 Jun;35(3):186-9.
doi: 10.1007/s15010-007-6068-1.

Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment

P L A Fraaij  1 , G Verweel, A M C van Rossum, N G Hartwig, D M Burger, R de Groot
Affiliations
Clinical Trial

Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment

P L A Fraaij et al. Infection. 2007 Jun.

Abstract

We here present the study results of 21 HIV-1 infected children who were treated with indinavir plus low-dose ritonavir and two nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. Although this q12h HAART regimen had potent antiretroviral activity, it was frequently associated with side effects and discontinuation of therapy.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1086/339443', 'is_inner': False, 'url': 'https://doi.org/10.1086/339443'}, {'type': 'PubMed', 'value': '11880968', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11880968/'}]}
    2. van Rossum AM, Geelen SP, Hartwig NG, Wolfs TF, Weemaes CM, Scherpbier HJ, et al.: Results of 2 years of treatment with protease- inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002;34:1008–1016. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '10877738', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10877738/'}]}
    2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al.: 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35–39. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(03)15022-2', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(03)15022-2'}, {'type': 'PubMed', 'value': '14683662', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14683662/'}]}
    2. Deeks SG: Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003;362:2002–2011. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PMC', 'value': 'PMC105944', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC105944/'}, {'type': 'PubMed', 'value': '9797204', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9797204/'}]}
    2. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, et al.: Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998;42:2784–2791. - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1097/00002030-200009290-00022', 'is_inner': False, 'url': 'https://doi.org/10.1097/00002030-200009290-00022'}, {'type': 'PubMed', 'value': '11061667', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11061667/'}]}
    2. van Rossum AM, de Groot R, Hartwig NG, Weemaes CM, Head S, Burger DM: Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection. AIDS 2000;14:2209–2210. - PubMed

Publication types